Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 2 June 2023, 11:20 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting

TOKYO, June 2, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.

Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).

Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.

For more information, visit www.eisai.com/news/2023/news202340.html.

Media Inquiries:

Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
TEL: +551-305-0050
Christopher_Vancheri@eisai.com


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 28, 2023 16:05 HKT/SGT
Eisai Launches New "Innovation" Page on Corporate Website
Sept 28, 2023 13:49 HKT/SGT
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Sept 25, 2023 14:17 HKT/SGT
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Sept 21, 2023 11:26 HKT/SGT
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Sept 12, 2023 18:05 HKT/SGT
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
Aug 4, 2023 12:04 HKT/SGT
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
July 20, 2023 10:23 HKT/SGT
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
July 12, 2023 09:05 HKT/SGT
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
July 7, 2023 12:21 HKT/SGT
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
June 30, 2023 10:08 HKT/SGT
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
More news >>
 News Alerts
Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: